Balancing Access and Innovation in India's Shifting IP Regime, Remarks

8 Pages Posted: 14 Aug 2014 Last revised: 1 May 2015

Ryan Abbott

University of Surrey School of Law; University of California, Los Angeles - David Geffen School of Medicine

Date Written: 2014

Abstract

This Article is based on a lecture that was delivered at the Whittier Law Review’s Annual Symposium on November 8, 2013, titled “The Global Medicine Challenge: The Fine Line Between Incentivizing Innovation and Protecting Human Rights.” It compares the pharmaceutical patent regimes of the United States and India, and discusses some of the inefficiencies of both systems. The Article analyzes the controversial Indian case of Novartis’ blockbuster drug Gleevec, and suggests that this case is an opportunity for both countries to consider changes to their patent laws. Smarter, rather than more, intellectual property protection could improve public health.

Suggested Citation

Abbott, Ryan, Balancing Access and Innovation in India's Shifting IP Regime, Remarks (2014). 35 Whittier Law Review 341 (2014). Available at SSRN: https://ssrn.com/abstract=2467819

Ryan Benjamin Abbott (Contact Author)

University of Surrey School of Law ( email )

Guildford
Guildford, Surrey GU2 5XH
United Kingdom

University of California, Los Angeles - David Geffen School of Medicine ( email )

1000 Veteran Avenue, Box 956939
Los Angeles, CA 90095-6939
United States

Paper statistics

Downloads
35
Abstract Views
175